文章目录

MyCheckpoint随机临床试验

原文发布日期：2024-08-26

英文摘要：

摘要翻译：

原文链接：

文章：

MyCheckpoint随机临床试验

the MyCheckpoint randomized clinical trial

原文发布日期：2024-08-26

英文摘要：

Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone (NCT04150965). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity. Durable clinical responses were observed in both the anti-TIGIT(three of six participants) and the anti-LAG3 (two of six participants) arms. Anti-LAG3 responders had higher naive cluster of differentiation 4 (CD4)-positive T cells and lower programmed cell death protein 1-positive effector T cells. Anti-TIGIT responders had higher CD226 expression, natural killer cell activation and lower CD112 expression. These data demonstrate the clinical activity of TIGIT–LAG3 blockade and identify pathway-specific response correlates in myeloma.

摘要翻译：

患有骨髓增生综合征的受试者随机接受抗TIGIT（T细胞免疫受体）或抗LAG3单克隆抗体后，联合帕马利妥和去甲基化酶（NCT04150965）。主要终点和次要终点分别为安全性及有效性。治疗过程中未出现限制性毒性反应。在抗TIGIT（三例中的六例受试者）和抗LAG3（两例中的六例受试者）研究组中，均观察到持久的临床反应。抗LAG3应答者的 naive T 细胞群（CD4+）及靶向 killing cell activation 明显增高，而 programed cell death protein 1+效应 T 细胞明显减少。抗TIGIT应答者 CD226 表达增多，自然杀伤细胞激活增强，CD112 表达减少。这些数据表明 TIGIT–LAG3 抑制剂的临床活性，并在骨髓增生综合征中识别出通路特异性应答相关联的通路。